CClinicalTrials.gg
Status unknownNCT05031377Updated Sep 1, 2021

Effects of Cardiovascular Health Education Program on Community-dwelling Older Adults at Risk of ASCVD

An interventional study of HE programme and Usual care in Cardiovascular Diseases, Healthy Lifestyle and Health Education, sponsored by The Hong Kong Polytechnic University. Status unknown. Open to participants aged 60 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-09-01.

Sponsored by The Hong Kong Polytechnic University · Not applicable, Interventional, and Prevention

The sponsor has not verified this record recently (last verified Aug 2021), so the status shown — last known as Not yet recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
60 Years and older
Sex
All
01

Study summary

Despite older adults being exposed to an increased risk of atherosclerotic cardiovascular disease (ASCVD), they are generally underrepresented in cardiovascular prevention programmes. The aim of this study is to assess the feasibility of implementing an integrated exercise and cardiovascular health education programme (HE programme) on older adults at risk of ASCVD.

Read the detailed description

The study is a two-arm pilot randomized controlled trial. (1) The control group will receive a basic lifestyle modification talk and governmental education leaflets. (2) The experimental group will receive an integrated exercise and health education programme (HE programme) based on self-efficacy theory. Physical activity level, exercise self-efficacy and ASCVD risk profile including blood pressure, cardiac endurance, and anthropometric outcomes will be investigated via physiological assessments, medical history-taking or questionnaires at baseline, Week 6, and Week 12. Meanwhile, study feasibility will be primarily evaluated in terms of programme acceptability, intervention integrity, recruitment rate and retention rate throughout the process and at Week 12.

02

Conditions studied

  • Cardiovascular Diseases
  • Healthy Lifestyle
  • Health Education

Keywords

  • Older Adults
  • Physical Activity
  • Atherosclerotic Cardiovascular Disease
  • Lifestyle Modification
  • Health Education
03

In context

Cardiovascular Diseases

4,904 studies on the registry are indexed under Cardiovascular Diseases; 919 are open to participants now.

This study's planned enrollment of 80 is below the median of 100 across 2,738 interventional studies indexed under Cardiovascular Diseases.

Browse Cardiovascular Diseases studies →

Lead sponsor

The Hong Kong Polytechnic University is the lead sponsor of 659 studies on the registry; 250 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Chinese adults ≧60 years old
  • Having at least one ASCVD risk factor
  • Pass the cardiovascular fitness evaluation
  • Able to write and read Chinese, and communicate in Cantonese;
  • Possess a mobile phone and able to make use of the phone in reading SMS

Exclusion criteria

Exclusion Criteria:

  • Visually impaired, hearing impaired, or suffer from cognitive, psychiatric, or muscular disorder
  • Having a history of attending similar cardiovascular prevention program
  • Having a previous history of coronary heart disease or stroke
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Experimental Arm: Integrated Intervention

    Receive an integrated exercise and cardiovascular health education programme (HE programme)

    Behavioral: HE programme

  • Sham comparator
    Control

    Receive usual care

    Behavioral: Usual care

Interventions

  • BehavioralHE programme

    Participants will receive a 12-week integrated exercise and cardiovascular health education programme (HE programme) which is constructed based on self-efficacy theory. A booster intervention in the form of SMS messaging will be given from Week 1 to Week 12.

  • BehavioralUsual care

    Participants will receive usual care which primarily includes an education talk on basic health issues. Governmental health education leaflets will be provided for reference.

06

What researchers measure

Primary outcomes

  1. Physical activity level (total score)

    The physical activity level will be measured by the Chinese Version of Physical Activity Scale for the Elderly (PASE-C). The total score (from zero to 400 or above) is quantified based on frequency values and weights for these activities. The higher the score, the higher the level of physical activity.

    Time frame: At baseline, at Week 6, and at Week 12

  2. Physical activity level (classification of physical activity level)

    The physical activity level will be measured by the Chinese version of International Physical Activity Questionnaire-short form (IPAQ-C-short form). Participants are classified into "inactive", "minimally active" or "health enhancing physical activity (HEPA) active" based on their physical activity levels.

    Time frame: At baseline, at Week 6, and at Week 12

Secondary outcomes

  1. Exercise self-efficacy

    Exercise self-efficacy will be measured via the Chinese version of Self-Efficacy for Exercise (SEE-C). The total score ranges from 0 to 90. The higher the score, the greater the exercise self-efficacy.

    Time frame: At baseline, at Week 6, and at Week 12

  2. ASCVD risk profiles (Blood pressure, weight, height, BMI & waist circumference, heart rate)

    The ASCVD risk profiles will be assessed by physical evaluations carried out by blinded, trained outcome assessors.

    Time frame: At baseline, at Week 6, and at Week 12

  3. ASCVD risk profiles (2-minute walk test)

    2-minute walk test will be adopted to examine aerobic capacity and self-paced walking capacity by measuring the walking distance covered at two minutes. It will be assessed by blinded, trained outcome assessors.

    Time frame: At screening stage, at Week 6, and at Week 12

  4. Acceptability of the program to participants

    It will be measured by a self-developed questionnaire

    Time frame: At Week 12

  5. Acceptability of the program to outcome assessors

    It will be measured by a self-developed questionnaire completed by outcome assessors

    Time frame: After the outcome assessors have finished their duties

  6. Acceptability of the program to lecture deliverers

    It will be measured by a self-developed questionnaire completed by lecture deliverers

    Time frame: After the lecture deliverers have finished their duties

  7. Adverse events throughout the program

    Unfavorable or unintended events regarding the programme reported by participants throughout the study period.

    Time frame: Throughout the study period

  8. Program safety evaluated by participants

    It will be measured via a self-developed questionnaire completed by participants

    Time frame: At Week 12

  9. Eligibility rate

    The number of eligible potential participants divided by the number of screened people

    Time frame: At baseline

  10. Recruitment rate

    The percentage of participants who consent to join the study and being recruited

    Time frame: At baseline

  11. Retention rate

    The percentage of participants remaining in the study

    Time frame: At baseline, at Week 6 and at Week 12

  12. Lecture attendance rate

    * The number of participants in the control group who attend the education talk divided by the number of participants who are randomized into the control group * The number of participants in the experimental group who attend the education session divided by the number of participants who are randomized into the experimental group * The number of participants in the two groups who attend the education session divided by the number of randomized participants

    Time frame: Immediately after education session

  13. Adherence to intervention

    * The number of participants in the experimental group who practice the tailor-made exercise learned during the intervention divided by the number of participants in the experimental group * Experimental group's frequency in performing tailor-made exercise related to the recommended exercise dosage

    Time frame: At Week 6 and at Week 12

  14. Attendance rate to data collection

    * The number of participants in the control group who attend the data collection divided by the number of participants who are randomized into the control group * The number of participants in the experimental group who attend the data collection divided by the number of participants who are randomized into the experimental group * The number of participants who attend the data collection divided by the number of randomized participants

    Time frame: At baseline, at Week 6 and at Week 12

  15. Questionnaire completion rate

    The number of participants who complete the questionnaire divided by the number of distributed questionnaires

    Time frame: At baseline, at Week 6 and at Week 12

  16. Missing data

    The percentage of missing data

    Time frame: At baseline, at Week 6 and at Week 12

  17. Structured questionnaire

    The questionnaire will primarily include patient demographics, medical history, lifestyle patterns, medication use and physical fitness evaluation data, etc.

    Time frame: At baseline

07

Study locations

No study locations are listed for this record.

08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 1, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05031377
Lead sponsor
The Hong Kong Polytechnic University
Responsible party
Dr Eva Ho (Assistant Professor, The Hong Kong Polytechnic University) — Principal investigator
First posted
Sep 1, 2021
Start date
Sep 1, 2021 (estimated)
Primary completion
Sep 1, 2024 (estimated)
Completion
Sep 1, 2024 (estimated)
Last update
Sep 1, 2021

Study contacts

Ka Yan Ho, PhD
Contact
kyeva.ho@polyu.edu.hk
27666417
Ka Yan Ho, PhD
study director · The Hong Kong Polytechnic University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion